Pfizer, Moderna and BioNTech

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.
The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.
Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.
Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.